

Hannah De Schutter<sup>1</sup>, Julie Hias<sup>1,2</sup>, Laura Hellemans<sup>1,2,3</sup>, Karolien Walgraeve<sup>1</sup>, Jos Tournoy<sup>4</sup>, Peter Verhamme<sup>5</sup>, Peter Sinnaeve<sup>5</sup>, Rik Willems<sup>5</sup>, Walter Droogné<sup>5</sup>, Christophe Vandembrielle<sup>5</sup>, Lucas Van Aelst<sup>5</sup>, Thomas Vanassche<sup>5</sup>, Lorenz Van der Linden<sup>1,2</sup>

<sup>1</sup>Pharmacy department, University Hospitals Leuven, Belgium; <sup>2</sup>Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; <sup>3</sup>Research Foundation Flanders, Brussels, Belgium; <sup>4</sup>Department of Public Health and Primary Care, University of Leuven and Department of Geriatric Medicine, University Hospitals Leuven, Belgium; <sup>5</sup>Department of Cardiovascular Diseases, University Hospitals Leuven, and Department of Cardiovascular Sciences, University of Leuven, Belgium  
Contact: Julie Hias: Julie.1.hias@uzleuven.be; Herestraat 49 3000 Leuven, Belgium

## BACKGROUND & IMPORTANCE



### BACKGROUND

- Cardiovascular therapies are **used frequently**, accounting for 50% of prescriptions in geriatric patients.
- They frequently cause **adverse drug events**.
- Yet, most interventional studies did not target these therapies. This might be attributed to a lack of resources, adequate training or support to perform targeted medication reviews.
- Consequently, there is a **clear need for an updated screening tool** targeting cardiovascular therapies in geriatric patients.



### AIM

To update and validate the cardiovascular segment of a previously developed screening tool, the RASP list<sup>1</sup>.

The updated **RASP\_CARDIO list** was intended for use in **geriatric patients**.

## RESULTS



**Seventeen experts** from four European countries participated in two validation rounds (Figure 1). Consensus was achieved for all statements of the RASP\_CARDIO list. One new statement was added.



The final construct comprised a list of **95 statements** related to potentially inappropriate prescribing (both over- and underuse) of cardiovascular agents.

## MATERIALS & METHODS

A **three step validation study** was conducted by the hospital pharmacy, geriatric medicine and cardiology departments of the University Hospitals Leuven


① **Update of RASP List (version 2014)<sup>1</sup>**: based on literature research, other screening tools and input of end-users

② **Panel discussions** with five cardiologist and three clinical pharmacists: review of updated draft RASP\_CARDIO list

③ **External validation using a modified Delphi Technique** and a panel of European hospital pharmacists, cardiologists, geriatricians and an internal medicine physician

Consensus was achieved in case of  $\geq 80\%$  agreement among experts. The final construct was compared to the cardiovascular segment of the STOPP/START criteria version 2<sup>2</sup>.

Figure 1: Origin of Delphi rounds participants



## RASP\_CARDIO ↔ STOPP/START v\_2


- 90%** (29/32) of the cardiovascular statements of the second version of the STOPP/START criteria were **included in the RASP\_CARDIO list**
- The RASP\_CARDIO list incorporated **66 additional statements**.

## CONCLUSION & RELEVANCE



The RASP\_CARDIO list is an **updated and validated explicit screening tool** to **optimize cardiovascular pharmacotherapy in geriatric patients**.

Scan for poster:



## REFERENCES

- Van der Linden L. (2014) Eur Geriatr Med 5(3):175–180
- O'Mahony D. (2015) Age Ageing 44(2):213–218

Scan for publication (including RASP\_CARDIO list):

